121 related articles for article (PubMed ID: 22417708)
1. The influence of antidiabetic medications on the development and progression of prostate cancer.
Hitron A; Adams V; Talbert J; Steinke D
Cancer Epidemiol; 2012 Aug; 36(4):e243-50. PubMed ID: 22417708
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy for diabetes is associated with increased use of lower endoscopy.
Lewis JD; Capra AM; Achacoso NS; Ferrara A; Levin TR; Quesenberry CP; Habel LA
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1195-202. PubMed ID: 17603822
[TBL] [Abstract][Full Text] [Related]
3. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study.
Horsdal HT; Søndergaard F; Johnsen SP; Rungby J
Pharmacoepidemiol Drug Saf; 2011 Apr; 20(4):331-7. PubMed ID: 21442682
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.
Koro CE; Bowlin SJ; Weiss SR
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):697-703. PubMed ID: 15654719
[TBL] [Abstract][Full Text] [Related]
6. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
7. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
8. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
9. Metformin use and prostate cancer risk.
Preston MA; Riis AH; Ehrenstein V; Breau RH; Batista JL; Olumi AF; Mucci LA; Adami HO; Sørensen HT
Eur Urol; 2014 Dec; 66(6):1012-20. PubMed ID: 24857538
[TBL] [Abstract][Full Text] [Related]
10. [Development of body weight during antidiabetic treatment].
Hamann A
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S255-8. PubMed ID: 17139582
[TBL] [Abstract][Full Text] [Related]
11. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
12. Association between metformin use and risk of prostate cancer and its grade.
Margel D; Urbach D; Lipscombe LL; Bell CM; Kulkarni G; Austin PC; Fleshner N
J Natl Cancer Inst; 2013 Aug; 105(15):1123-31. PubMed ID: 23853056
[TBL] [Abstract][Full Text] [Related]
13. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
[TBL] [Abstract][Full Text] [Related]
14. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.
Bodmer M; Becker C; Meier C; Jick SS; Meier CR
Am J Gastroenterol; 2012 Apr; 107(4):620-6. PubMed ID: 22290402
[TBL] [Abstract][Full Text] [Related]
15. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.
Koro C; Barrett S; Qizilbash N
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):485-92. PubMed ID: 17192841
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
17. Anti-diabetic drug use and the risk of motor vehicle crash in the elderly.
Hemmelgarn B; Lévesque LE; Suissa S
Can J Clin Pharmacol; 2006; 13(1):e112-20. PubMed ID: 16585812
[TBL] [Abstract][Full Text] [Related]
18. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection.
Kawaguchi T; Taniguchi E; Morita Y; Shirachi M; Tateishi I; Nagata E; Sata M
Liver Int; 2010 Mar; 30(3):479-86. PubMed ID: 20040053
[TBL] [Abstract][Full Text] [Related]
19. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
20. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
Hsu CC; Wahlqvist ML; Lee MS; Tsai HN
J Alzheimers Dis; 2011; 24(3):485-93. PubMed ID: 21297276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
